Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schnell, R.
Right arrow Articles by Engert, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schnell, R.
Right arrow Articles by Engert, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:57-66, 2002
© 2002 European Society for Medical Oncology

Current strategies of antibody-based treatment in Hodgkin's disease

R. Schnell1, P. Borchmann1, H. Schulz1 and A. Engert1

1 Klinik I für Innere Medizin, Universität zu Köln, Köln, Germany

Abstract

Many new approaches involving antibody-based agents have given promising results in experimental Hodgkin's disease (HD) models. Clinical trials with monoclonal antibodies, immunotoxins, bispecific constructs and radioimmunoconjugates have demonstrated some clinical efficacy in patients with advanced refractory HD. Although it seems unlikely that resistant patients with larger tumor masses will be cured by either of these approaches, it might be feasible to treat bulky disease by conventional therapy and then administer biological agents to kill residual Hodgkin and Reed–Sternberg cells. Future phase III trials will have to prove a possible superior effect of this combined immunochemotherapy. Currently, the evaluation of the most promising approaches continues.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Int ImmunolHome page
S.-Y. Nam, Y.-H. Kim, J.-S. Do, Y.-H. Choi, H.-J. Seo, H.-K. Yi, P.-H. Hwang, C.-H. Song, H.-K. Lee, J.-S. Kim, et al.
CD30 supports lung inflammation
Int. Immunol., February 1, 2008; 20(2): 177 - 184.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
Y. E. Lieskovsky, S. S. Donaldson, M. A. Torres, R. M. Wong, M. D. Amylon, M. P. Link, and R. Agarwal
High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation for Recurrent or Refractory Pediatric Hodgkin's Disease: Results and Prognostic Indices
J. Clin. Oncol., November 15, 2004; 22(22): 4532 - 4540.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. von Tresckow, K.-J. Kallen, E. P. von Strandmann, P. Borchmann, H. Lange, A. Engert, and H. P. Hansen
Depletion of Cellular Cholesterol and Lipid Rafts Increases Shedding of CD30
J. Immunol., April 1, 2004; 172(7): 4324 - 4331.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Schnell, P. Borchmann, J. O. Staak, J. Schindler, V. Ghetie, E. S. Vitetta, and A. Engert
Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma
Ann. Onc., May 1, 2003; 14(5): 729 - 736.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
U. Rehwald, H. Schulz, M. Reiser, M. Sieber, J. O. Staak, F. Morschhauser, C. Driessen, T. Rudiger, K. Muller-Hermelink, V. Diehl, et al.
Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group
Blood, January 15, 2003; 101(2): 420 - 424.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
V. Diehl, H. Stein, M. Hummel, R. Zollinger, and J. M. Connors
Hodgkin's Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease
Hematology, January 1, 2003; 2003(1): 225 - 247.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.